Adaptimmune Therapeutics PLC – ADR (ADAP) was Initiated by Raymond James to “Outperform” and the brokerage firm has set the Price Target at $16. Raymond James advised their investors in a research report released on Sep 30, 2016.
Adaptimmune Therapeutics PLC – ADR opened for trading at $7.15 and hit $7.4 on the upside on Tuesday, eventually ending the session at $7.2, with a gain of 0.98% or 0.07 points. The heightened volatility saw the trading volume jump to 4,06,588 shares. Company has a market cap of $510 M.
In a different news, on May 25, 2016, Peter A. Thompson (director) purchased 1,712,400 shares at $10.31 per share price. According to the SEC, on May 19, 2016, Charles Elliott Sigal (director) purchased 15,000 shares at $1.56 per share price.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor platform. The Company has developed a platform that enables to identify cancer targets in the form of peptides which are short sequences of amino acids find and genetically engineer T-cell receptors (TCRs) and produce TCR therapeutic candidates for administration to patients. The Company’s target peptides are NY-ESO-1 and MAGE A-10. The Company’s affinity-enhanced TCR therapeutics targets the NY-ESO-1 or NY-ESO cancer antigen. The Company has completed the Phase I/II clinical trials for its NY-ESO TCR therapeutic candidate in patients with solid tumors and hematological malignancies including synovial sarcoma multiple myeloma melanoma ovarian cancer and esophageal cancer.